Amycretin (now named zenagamtide) is a single molecule from Novo Nordisk that acts on both GLP-1 and amylin receptors. It is being tested as a once-weekly injection and a once-daily pill for weight loss and type 2 diabetes, and is not FDA approved.
Also known as: zenagamtide.
There is no approved product. As a weekly injection, the phase 1b/2a obesity trial stepped people up from 0.3 mg to 1.25, 5, 20 or 60 mg (Dahl 2025), and the phase 2 diabetes trial used 0.4 to 40 mg (Mora 2026). As a daily pill, the diabetes trial used 6, 25 or 50 mg (Mora 2026). These are trial protocols, not personalized advice; confirm any dosing with your prescriber.
Amycretin is not FDA approved; it is investigational, and we found no product in FDA's Drugs@FDA database. The 2026 phase 2 papers call it zenagamtide (formerly amycretin) and describe it as acting on GLP-1, amylin and calcitonin receptors.
In the phase 1b/2a injection trial (Dahl 2025; 125 adults with overweight or obesity), average weight change was −24.3% on 60 mg and −22.0% on 20 mg at week 36, −16.2% on 5 mg at week 28 and −9.7% on 1.25 mg at week 20, versus −1.1% to +2.3% on placebo. Most side effects were gastrointestinal and mild to moderate, and many people dropped out. A first trial of the pill (Gasiorek 2025) tested single and daily doses in adults with overweight or obesity.
In the phase 2 diabetes trials (Mora 2026; 36 weeks), HbA1c fell by 0.9% to 1.7% on the weekly shot and 0.9% to 1.4% on the daily pill, depending on dose. Gastrointestinal side effects were the most common.
The trial summaries we read report blood levels but give no half-life or time to peak, so we do not list one.
How Dose Track handles GLP-1s · Reconstitution calculator · Half-life calculator